**DEMOGRAPHICS OF THE CATCHMENT POPULATION**

The SCC catchment area includes 82 counties in Missouri (40) and Illinois (42) within

~100-mile radius of SCC. 87% of new patients (2018) reside in the catchment.

The racial distribution of the catchment is 79.5% non-Hispanic White and 20.5%

minority (13.7% African American, 2% Asian, and 4.8% multiracial or other minority).

2.7% of the catchment population identifies as Hispanic/Latino ethnicity.

15% of the catchment reside in a rural area.

29% of the catchment reside in a medically underserved area (MUA).

*Source: 2018 American Community Survey (https://factfinder.census.gov/faces/nav/jsf/pages/community\_facts.xhtml) Retrieved 4/18/19*

This report intends to provide a description of cancer in the Siteman Cancer Center (SCC) catchment, as well as the demographics of cancer patients treated at SCC. The Research Program Reports will also provide current recruitment numbers for Tumor Immunology Program (TIP) clinical trials, including demographics of patients enrolled on trial. Minority is defined as self-identified race other than non-Hispanic white and includes Hispanic ethnicity. Unknown race or ethnicity is not considered minority. Rural is defined as RUCA ≥7.

**DEMOGRAPHICS OF THE SCC PATIENT POPULATION (ALL SITES)**

The racial distribution of the SCC patient population in 2018 is 83.1%% non-Hispanic White and 16.9% minority (12.4% African American, 1.4% Asian, and 3.1% multiracial or other minority).

0.3% of the SCC patient population identifies as Hispanic/Latino ethnicity.

13% of SCC patients reside in a rural zip code.

27% of SCC patients reside in a medically underserved area (MUA).

Of note, 48.5% of rural patients live in a MUA.

*Source: 01/2018 – 12/2018 newly diagnosed cancer patients at Siteman Cancer Center*

**DEMOGRAPHICS OF SCC CANCER PATIENTS**

In 2017, SCC reported a total of 3862 new cancer cases across all sites. Of these patients, a total of 81.8% were White (n=3159), 16.2% Black (n=627), and 2.0% (n=76) Other Minorities. This percentage of minority patients seen at SCC is used to define the minority accrual goal for TIP.

*Source: 01/2017 – 12/2017 cancer patients from SCC Tumor Registry (SCC, BJC-WC, BJC-SP)*

**The minority accrual goal for TIP clinical trials is 18.2%.**

**CANCER BURDEN IN THE CATCHMENT**

**Table 1** presents county-level age-adjusted incidence and mortality rates from 2012-2016 by race for Missouri, Illinois, and our catchment counties.

**Table 1. All Sites Cancer Incidence and Mortality (2012-2016)**

|  |  |  |
| --- | --- | --- |
|  | **Incidence (All Stages)****(AAR per 100k)** | **Mortality****(AAR per 100k)** |
|  | **Total** | **Black** | **White** | **Total** | **Black** | **White** |
| Catchment | 481.5 | 505.1 | 481.4 | 186.0 | 225.3 | 186.6 |
| Missouri | 455.2 | 481.4 | 453 | 175.6 | 212 | 173.5 |
| Illinois | 466.2 | 487.9 | 468.3 | 168.5 | 210.6 | 166.5 |
| U.S. | 448 | 450.4 | 450.1 | 161 | 185.6 | 161.5 |

*Source: State Cancer Profiles 2012-2016 (https://statecancerprofiles.cancer.gov), Average Annual Counts Retrieved 8/12/19*

**Figures 1-2** provide a comparison of the catchment to national rates for cancer incidence and mortality.

***Within the catchment, overall cancer incidence and mortality is higher in the catchment compared to the national rates. In addition, both incidence and mortality are higher for Black patients compared to Whites.***

*Source: State Cancer Profiles 2012-2016 (https://statecancerprofiles.cancer.gov), Retrieved 8/12/19*

**CANCER BURDEN AT SCC**

**Table 2** presents the number of colorectal, pancreas, lung, breast, uterine, and prostate cancer by race for 2013-2017. **In the most recent 5-year period at SCC, 79.9% of patients were White, 17.4% were Black, and 2.7% were other minorities.**

**Table 2. SCC Tumor Registry Cancer Incidence (2013-2017)**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|   | 2013 | 2014 | 2015 | 2016 | 2017 | 5-year total |
|   | # | % | # | % | # | % | # | % | # | % | # | % |
| Black | 621 | 17.2 | 627 | 16.7 | 596 | 15.7 | 619 | 16.3 | 627 | 16.2 | 3090 | 16.4 |
| Other Minority | 55 | 1.5 | 64 | 1.7 | 61 | 1.6 | 71 | 1.9 | 76 | 2.0 | 327 | 1.8 |
| Total Minority | 676 | 18.7 | 691 | 18.4 | 657 | 17.3 | 690 | 18.2 | 703 | 18.2 | 3417 | 18.2 |
| White | 2941 | 81.3 | 3069 | 81.6 | 3131 | 82.7 | 3099 | 81.8 | 3159 | 81.8 | 15399 | 81.8 |
|   | 3617 |  | 3760 |  | 3788 |  | 3789 |   | 3862 |   | 18816 |   |

*Source: 2013 – 2017 cancer patients from SCC Tumor Registry (SCC, BJC-WC, BJC-SP)*

**Figure 3** graphs the last 5 years of Tumor Registy Data to show the trends in % minority.

**Pooled 5-year data (2013-2017) for all cancers treated at SCC shows that 20.1% of SCC newly diagnosed cancer patients are minority.**

**TUMOR IMMUNOLOGY PROGRAM CLINICAL TRIAL ACCRUALS**

**Table 3** presents the demographics of patients enrolled in TIP clinical. The goal for percent minority enrollment is 18.2%, which is based on the most recent (2018) SCC minority patient population.

***In 2018, TIP minority accrual was 12.0%, below the goal of 18.2%. The 2019 minority accruals are currently 12.8%.***

**Table 3. Minority Accruals for TIP (2015-2019)**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | 2015 | 2016 | 2017 | 2018 | 2019 |
|   | # | % | # | % | # | % | # | % | # | % |
| Am. Indian / AK native | 1 | 0.3% | 0 | 0% | 1 | 0.2% | 0 | 0% | 0 | 0% |
| Asian / HI / Pac. Isle. | 6 | 1.9% | 3 | 0.8% | 7 | 1.4% | 4 | 0.7% | 2 | 0.7% |
| Black | 23 | 7.2% | 31 | 8.1% | 49 | 9.7% | 58 | 9.6% | 28 | 9.4% |
| Other (Minority) | 3 | 0.9% | 5 | 1.3% | 4 | 0.8% | 10 | 1.7% | 8 | 2.7% |
| Hispanic | 7 | 2.2% | 5 | 1.3% | 4 | 0.8% | 2 | 0.3% | 0 | 0% |
| **All Minorities** | **37** | **11.6%** | **42** | **11.0%** | **64** | **12.7%** | **73** | **12.0%** | **38** | **12.8%** |
| White | 281 | 88.4% | 341 | 89.0% | 441 | 87.3% | 533 | 88.0% | 259 | 87.2% |
| Total  | 318 |  | 383 |  | 505 |  | 606 |  | 297 |  |

*Source: OnCore Accruals Report Retrieved 09/04/19*

**Table 4** presents minority accrual numbers for each type of TIP trial enrolling patients between 2015 and August 2019. TIP includes summary accruals, comprised of batched datasets that may lack demographic information. The total number of accruals is therefore higher than the numbers reported in Table 4 because many summary patient records exclude demographic data and cannot be included in minority calculations.

***In 2018, minority accrual numbers for Interventional Treatment Trials were 12.1%, which is below the goal of 18.2%. Currently for 2019, TIP minority accruals are 12.9%.***

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | 2015 | 2016 | 2017 | 2018 | 2019 |
|  | # | % | # | % | # | % | # | % | # | % |
| Observational | 019 | 0% | 640 | 15.0% | 12120 | 10.0% | 764 | 10.9% | 122 | 4.5% |
| Ancillary/Correlative | 1142 | 26.2% | 410 | 40.0% | 58 | 62.5% | 759 | 11.9% | 318 | 16.7% |
| Interventional | 26257 | 10.1% | 32332 | 9.6% | 46370 | 12.4% | 53440 | 12.0% | 31241 | 12.9% |
| Treatment | 26249 | 10.4% | 32331 | 9.7% | 46366 | 12.6% | 53439 | 12.1% | 31241 | 12.9% |
| All Trial Types | 37318 | 11.6% | 42383 | 11.0% | 64505 | 12.7% | 73606 | 12.0% | 38297 | 12.8% |

 *Source: OnCore Accruals Report Retrieved 09/04/19*

**Table 5** presents a summary directly comparing the Catchment population, SCC patient population, and TIP Clinical Trial accruals.

**Table 5. Summary of TIP Accruals Compared to the Catchment and SCC Patient Populations**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | Catchment | SCC Patients | TIPAll Trials | TIPTreatment Trials |
|   | 2018 | 2018 | 2018 | 2019 | 2018 | 2019 |
| Catchment | -- | 87% | 81.5% | 82.2% | 78.6% | 80.5% |
| Rural | 15% | 13% | 14.4% | 14.5% | 14.8% | 15.8% |
| MUA | 29% | 27% | 21.6% | 18.9% | 21.4% | 19.5% |
| Minority | 20.5% | 16.9% | 12.0% | 12.8% | 12.1% | 12.9% |
| Black | 13.7% | 12.4% | 9.6% | 9.4% | 9.8% | 9.5% |
| Asian | 2.0% | 1.4% | 0.7% | 0.7% | 0.5% | 0.8% |
| Other Race | 2.7% | 3.1% | 1.7% | 2.7% | 1.6% | 2.5% |
| Hispanic | 4.8% | 0.3% | 0% | 0% | 0.5% | 0.4% |
| Non-Hispanic White | 79.5% | 83.1% | 88.0% | 87.2% | 87.9% | 87.1% |